Arthneeti
Latest: Privi Speciality Chemicals Ltd Q2 FY27 results →All Q4 FY26 results →
PS

Privi Speciality Chemicals Ltd

Q4 FY26Chemicals & Petrochemicals

Privi Speciality Chemicals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹3,480
Market cap₹14.3K Cr
P/E40.7
Updated23 Aug 2026
Read4 min read

The short version

The company targets around 20% growth in revenues for the coming year (FY27). Privi Speciality Chemicals aims to achieve approximately INR 5,000 crore revenue and INR 1,000 crore+ EBITDA within the next 3 to 4 years, representing about 2x growth from current levels.

From Privi Speciality Chemicals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets around 20% growth in revenues for the coming year (FY27).
  • Volume growth contributed about 6.5% in FY26; future volume growth is expected alongside product mix and pricing improvements.
  • Planned capacity expansion will increase installed capacity to 54,000 metric tons per annum by June 2026.
  • New speciality aroma chemicals projects (Phase 2 and Phase 3) are underway, expected to be commissioned by June FY27, supporting further revenue growth.
  • The JV with PRIGIV is scaling up rapidly, projecting around INR130 crore sales in this year versus INR55 crore last year, aiming for INR300 crore in 3-4 years.

2 more points from Privi Speciality Chemicals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Privi Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • A demonstration plant for biotechnology and biowaste conversion is being set up with a capex of around INR 70-75 crore, expected to operate within 12 months, to assess economics and commercial viability of biotech routes.
  • Phase 2 and Phase 3 capex expansions are underway, with new product projects (ethyl maltol, maltol, cyclopentanone) targeted for commissioning by June FY27; detailed engineering and procurement in progress.
  • PRIGIV joint venture has an additional capex of INR 50 crore from equity infusion (Privi 51%, Givaudan 49%) aimed at growing revenue and profitability.
  • Backward integration for furfural is planned post-2 years, likely FY28-29, as a separate capex initiative.

2 more points from Privi Speciality Chemicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Privi Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points related to ongoing business and outlook include: - The company is focused on specialty chemicals with multiple new product launches targeted in the next 1-3 years. - They have confirmed ongoing discussions and partnerships with multinational companies like Givaudan. - PRIGIV, a specialized business segment, is expected to contribute around INR 130 crore revenue in the current year, up from INR 55 crore. - The company expects to maintain strong revenue growth (~20% guided) and EBITDA margins (~25%).

2 more points from Privi Speciality Chemicals Ltd's call on order book

Create a free account to keep reading this call

Privi Speciality Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹760 Cr, net profit ₹118 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Privi Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate Ltd (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Paragon Fine (Q4 FY26)

    Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p

  • IVP Ltd (Q4 FY26)

    Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector

  • Vishnu Chemicals Ltd (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Privi Speciality Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Privi Speciality Chemicals Ltd Q4 FY26 results?

The company targets around 20% growth in revenues for the coming year (FY27). Privi Speciality Chemicals aims to achieve approximately INR 5,000 crore revenue and INR 1,000 crore+ EBITDA within the next 3 to 4 years, representing about 2x growth from current levels.

What is Privi Speciality Chemicals Ltd share price analysis?

Privi Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 40.7 with a market cap of ₹14,250 Cr. Investors should review the full earnings analysis for detailed insights.

Is Privi Speciality Chemicals Ltd planning capital expenditure?

A demonstration plant for biotechnology and biowaste conversion is being set up with a capex of around INR 70-75 crore, expected to operate within 12 months, to assess economics and commercial viability of biotech routes.

Keep Privi Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.